

Reimbursement Coding Options for Hospital Outpatient and ASC Services

QUZYTIR™ (cetirizine hydrochloride injection), 10mg/mL, for intravenous use

Disclaimer: It is important to note that the codes identified below are examples only. Each provider is responsible for ensuring all coding is accurate and documented in the medical record based on the condition of the patient. The use of the following codes does not guarantee reimbursement. The ultimate responsibility for obtaining reimbursement lies with the physician, provider, or patient. Please consult with your reimbursement specialist for any practice-specific reimbursement or billing questions.

National Drug Code (NDC)

The NDC is a universal product identifier comprised of a 3-segment number that identifies drugs by manufacturer, dosage, and package size. Payers may require the submission of an 11-digit NDC on healthcare claim forms, and electronic claims may be denied for drugs billed without a valid 11-digit NDC. Contact your patient's health plan to determine claim submission requirements and to determine accurate reporting of NDC codes.

Dosage	11 Digit Code
Carton containing 25 single-use vials (10mg/mL cetirizine hydrochloride)	70720-0100-25

Current Procedural Terminology (CPT)

Submitting accurate codes and claims is important to ensure proper reimbursement of services. The chart below lists the potential CPT codes for your reference when submitting claims for your patients who receive QUZYTIR.

Code	Description
96374	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug.
96375	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (list separately in addition to code for primary procedure).
96376	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of the same substance/drug provided in a facility (list separately in addition to code for primary procedure).

Healthcare Common Procedure Coding System (HCPCS)

Submitting accurate codes and claims is important to ensure proper reimbursement of services. The chart below lists the potential code for your reference when submitting claims for your patients who receive QUZYTIR.

Code	Short Description	Long Description
C9057	Inj cetirizine hydrochloride	Injection, cetirizine hydrochloride, 1mg

This J-code is effective July 1, 2020*

Code	Description
*J1201	Injection, cetirizine hydrochloride, 0.5mg

- A CMS 1450 (UB-40) form is often required
- Please enter the following information in box 43:
 - o N4 indicator, 11-digit NDC, code describing unit of measurement, unit quantity (Example: N470720010025ME10).
- Please enter the following information in box 44:
 - o The appropriate HCPCS code for QUZYTIR use as required by the payer
 - C9057 may be appropriate for Medicare Part B or,
 - J3490, unclassified drug, may be appropriate for other payers through June 30, 2020
 - J1201 may be appropriate after July 1, 2020
- Check with your individual payer for specific requirements

Diagnosis Code (ICD-10)

Submitting accurate codes and claims is important to ensure proper reimbursement of services. The chart below lists potential diagnosis codes for your reference when submitting claims for your patients who receive QUZYTIR™ (cetirizine hydrochloride injection), for intravenous use.

Code	Description
L50	Urticaria
L50.0	Allergic urticaria
L50.1	Idiopathic urticaria
L50.2	Urticaria due to cold and heat
L50.3	Dermatographic urticaria
L50.4	Vibratory urticaria
L50.5	Cholinergic urticaria
L50.6	Contact urticaria
L50.8	Other urticaria
L50.9	Urticaria, unspecified

Additional Questions?

Please contact TerSera SupportSource at 1-855-686-8725, Monday-Friday, 9:00 AM -6:00 PM EST.



Indication and Important Safety Information QUZYTIR™ (cetirizine hydrochloride injection), for intravenous use

INDICATIONS AND USAGE

QUZYTIR is indicated for the treatment of acute urticaria in adults and children 6 months of age and older.

Limitations of Use: QUZYTIR is not recommended in pediatric patients <6 years of age with impaired renal or hepatic function.

IMPORTANT SAFETY INFORMATION

Contraindications: Known hypersensitivity to QUZYTIR or any of its ingredients, to levocetirizine, or hydroxyzine.

Warnings and Precautions: The occurrence of somnolence/sedation has been reported in some patients. Advise patients to exercise due caution when driving or operating potentially dangerous machinery. Avoid concurrent use of QUZYTIR with alcohol or other CNS depressants because additional reduction in alertness and additional impairment of CNS performance may occur.

Adverse Reactions: The most common adverse reactions (incidence <1%) with QUZYTIR are dysgeusia, headache, paresthesia, presyncope, dyspepsia, feeling hot, and hyperhidrosis.

The most common adverse reactions (incidence $\geq 2\%$) with chronic dosing of oral cetirizine hydrochloride in adults are somnolence, fatigue, dry mouth, pharyngitis and dizziness. Adverse reactions observed in pediatric patients with chronic use of oral cetirizine hydrochloride are headache, pharyngitis, abdominal pain, coughing, somnolence, diarrhea, epistaxis, bronchospasm, nausea, and vomiting.

For more information, please see the accompanying full Prescribing Information for QUZYTIR.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.